

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

TA187; Infliximab and adalimumab for the treatment of Crohn's disease

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Amgen (adalimumab biosimilar) • Biogen Idec (infliximab biosimilar) • Hospira UK (infliximab biosimilar) • Merck Sharp and Dohme (infliximab) • Napp Pharmaceuticals (infliximab biosimilar) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • Bowel Cancer UK • Colostomy Association • Crohn's and Colitis UK • forCrohn's • IA: Ileostomy and Internal Pouch Support Group • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Coloproctology of Great Britain and Ireland • British Geriatrics Society • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Accord Healthcare (ciprofloxacin, methotrexate) • Actavis UK (azathioprine, metronidazole, prednisolone, sulfasalazine) • Allergan (mesalazine, prednisolone) • Alliance Pharmaceuticals (prednisolone) • Almirall (balsalazide disodium) • Almus Pharmaceuticals (azathioprine, metronidazole, prednisolone sulfasalazine) • Aspen Pharma (azathioprine, mercaptopurine) • Atnahs Pharma UK (olsalazine sodium) • Aurobindo Pharma – Milpharm (ciprofloxacin, metronidazole)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • NHS England • Welsh Government • NHS Corby CCG • NHS Erewash CCG 	<ul style="list-style-type: none"> • Bayer (ciprofloxacin, prednisolone) • Beacon Pharmaceuticals (methylprednisolone) • Bristol Laboratories (ciprofloxacin) • Colorama Pharmaceuticals (ciclosporin) • Concordia International (hydrocortisone, methotrexate, prednisolone) • Consillient Health (ciprofloxacin) • Crescent Pharma (metronidazole, prednisolone) • Cubic Pharmaceuticals (ciclosporin) • Dexcel Pharma (ciclosporin) • Dr Falk Pharma UK (budesonide melsalazine) • Dr. Reddy's Laboratories UK (ciprofloxacin) • Essential Generics (prednisolone) • Ferring Pharmaceuticals (melsalazine) • Genesis Pharmaceuticals (prednisolone, sulfasalazine) • Hospira UK (ciprofloxacin, methotrexate) • Icarus Pharmaceuticals (ciclosporin) • Intraparm Laboratories (prednisolone) • Kent Pharmaceuticals (ciprofloxacin, metronidazole) • Logixx Pharma Solutions (prednisolone) • Marlborough Pharmaceuticals (olsalazine sodium) • Medac (methotrexate) • Medreich (ciprofloxacin) • Morningside Healthcare (ciclosporin, methotrexate) • Mylan (azathioprine, ciclosporin, ciprofloxacin) • Napp Pharmaceuticals (prednisolone) • Nordic Pharma (methotrexate) • Nova Laboratories (mercaptopurine) • Novartis (ciclosporin) • Orion Pharma UK (methotrexate) • Pfizer (hydrocortisone, methotrexate, methylprednisolone, sulfasalazine) • Phoenix Labs (prednisolone) • Ranbaxy UK (ciprofloxacin) • Rosemont Pharmaceuticals

Consultees	Commentators (no right to submit or appeal)
	<p>(methotrexate, metronidazole, sulfasalazine)</p> <ul style="list-style-type: none"> • Sandoz (azathioprine, methotrexate) • Sanofi (metronidazole, sodium cromoglicate) • Shire Pharmaceuticals (mesalazine) • Strides Shasun UK (azathioprine, ciprofloxacin, prednisolone) • Takeda UK (vedolizumab) • Teva UK (azathioprine, ciclosporin, methotrexate, metronidazole, prednisolone) • Tillomed Laboratories (azathioprine, ciprofloxacin) • Tillotts Pharma UK (budesonide, mesalazine) • UCB Pharma (olsalazine) • Waymade Healthcare (ciprofloxacin, methotrexate, metronidazole, prednisolone, sulfasalazine) • Wockhardt UK (ciprofloxacin, prednisolone) • Zentiva (metronidazole, prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • CORE (Digestive Disorders Foundation) • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.